- Price
- $11.22
- Day
- +4.76%
- Mkt Cap
- $517.20M
- 52W Range
- $9.72 – $20.36
- Volume
- 519.7K
- Beta
- 1.01
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Core Laboratories NYSE: CLB reported second-quarter 2026 revenue of $124.6 million, up more than 2% from the prior quarter but down 4% from a year earlier, as stronger completion-product sales partly offset disruptions to its service business from conflicts in the Middle East and Russia-Ukraine.
Read full article
CLB's Q2 earnings top estimates despite lower revenues and profit as Production Enhancement strength offsets Reservoir Description weakness.
Read full article
Core Laboratories stock looks cheaper after a 47.1% six-month selloff, but falling earnings and geopolitical pressure keep the near-term case cautious.
Read full article
Core Laboratories Inc. (CLB) Q2 2026 Earnings Call Transcript
Read full article
REVENUE OF $ 124.6 MILLION, UP 2% SEQUENTIALLY AND DOWN 4% YEAR-OVER-YEAR OPERATING INCOME OF $ 9.2 MILLION; EX-ITEMS, $9.4 MILLION, UP 42% SEQUENTIALLY AND DOWN 36% YEAR-OVER-YEAR GAAP EARNINGS PER SHARE OF $0.13; EPS EX-ITEMS OF $0.11, UP 85% SEQUENTIALLY AND DOWN 42% YEAR-OVER-YEAR FREE CASH FLOW OF $ 3.1 MILLION COMPANY REPURCHASED 214,712 SHARES OF COMMON STOCK, FOR $2.7 MILLION AGGREGATE PURCHASE PRICE COMPANY ANNOUNCES Q3 2026 QUARTERLY DIVIDEND HOUSTON, July 29, 2026 /PRNewswire/ -- Core Laboratories Inc. (NYSE: "CLB") ("Core," "Core Lab," or the "Company") reported second quarter 2026 revenue of $124,600,000. Core's operating income was $9,200,000, with earnings per diluted share ("EPS") of $0.13, all in accordance with U.S. generally accepted accounting principles ("GAAP").
Read full article
Core Laboratories (CLB) came out with quarterly earnings of $0.11 per share, beating the Zacks Consensus Estimate of $0.08 per share. This compares to earnings of $0.19 per share a year ago.
Read full article
The Ariel Small/Mid Cap Value Composite rose +15.08% gross of fees (+14.95% net of fees) in the quarter, falling short of both the Russell 2500 Value Index's +18.50% return and the +20.26% gain posted by the Russell 2500 Index. Live entertainment, media, and technology company, Sphere Entertainment Co. was the top contributor during the quarter on solid earnings and improving operating fundamentals. Shares of Prestige Consumer Healthcare moved lower following disappointing earnings, driven primarily by ongoing supply constraints in its eye care segment and extended lead times in the Middle East.
Read full article
CLB's Q2 may reflect resilient international activity and tariff insulation, but weaker reservoir description results and higher costs could weigh.
Read full article
Core Laboratories (CLB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read full article
CLB struggles with ongoing headwinds from lower completion activity, operational disruptions, inflationary costs, weaker margins and projected earnings decline in 2026.
Read full article